A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.

Spelman, Tim; Ozakbas, Serkan; Alroughani, Raed; Terzi, Murat; Hodgkinson, Suzanne; Laureys, Guy; Kalincik, Tomas; Der Walt, Anneke Van; Yamout, Bassem; Lechner-Scott, Jeannette; Soysal, Aysun; Kuhle, Jens; Sanchez-Menoyo, Jose Luis; Morgado, Yolanda Blanco; Spitaleri, Daniele LA; Pesch, Vincent van; Horakova, Dana; Ampapa, Radek; Patti, Francesco; Macdonell, Richard A L; Al-Asmi, Abdullah; Gerlach, Oliver; Oh, Jiwon; Altintas, Ayse; Tundia, Namita; Wong, Schiffon L; Butzkueven, Helmut

doi:10.2217/nmt-2023-0005

Title

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.

Publication Date

2023-08

Author(s)

Spelman, Tim

Ozakbas, Serkan

Alroughani, Raed

Terzi, Murat

Hodgkinson, Suzanne

Laureys, Guy

Kalincik, Tomas

Der Walt, Anneke Van

Yamout, Bassem

Lechner-Scott, Jeannette

Soysal, Aysun

Kuhle, Jens

Sanchez-Menoyo, Jose Luis

Morgado, Yolanda Blanco

Spitaleri, Daniele LA

Pesch, Vincent van

Horakova, Dana

Ampapa, Radek

Patti, Francesco

Macdonell, Richard A L

Al-Asmi, Abdullah

Gerlach, Oliver

Oh, Jiwon

Altintas, Ayse

Tundia, Namita

Wong, Schiffon L

Butzkueven, Helmut

Subject

cladribine tablets

dimethyl fumarate (Tecfidera®)

fingolimod (Gilenya®)

lay summary

multiple sclerosis

relapses

teriflunomide (Aubagio®)

treatment options

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.2217/nmt-2023-0005

Abstract

Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.

Link

link

Citation

Neurodegenerative Disease Management 2023; 13(4)

Jornal Title

Neurodegenerative Disease Management

ISSN

1758-2032

Austin Health

Files: